This Medical Letter review summarizes antibiotic regimens to treat the dermatological, neurological, cardiac, and rheumatological manifestations of Lyme disease.
Most cases of Lyme disease in the US occur between May and September in the Northeastern, Mid-Atlantic, and North Central states.
Once a month, The Medical Letter provides a previously published article to JAMA to be republished.
Previous Publication: This article was published in The Medical Letter on Drugs and Therapeutics. May 9, 2016;58(1494):57-58. It is reprinted here with permission from ©The Medical Letter Inc.
For a free trial subscription to The Medical Letter, go to www.medicalletter.org/tmlj. The Medical Letter—Essential to your practice.
About The Medical Letter: The Medical Letter is a nonprofit organization that publishes biweekly new drug evaluations and treatment recommendations. The Medical Letter does not accept advertisements, gifts, grants, or donations. Financial support comes solely from sales of subscriptions, books, software, continuing education materials, and licenses.
Editors: Mark Abramowicz, MD, President; Gianna Zuccotti, MD, MPH, Vice President and Executive Editor; Jean-Marie Pflomm, PharmD, Editor in Chief